Trial Profile
An open label multi facilities cooperation randomized control trial for prevention Evolution of Diabetic nephrOpathy by Olmesartan.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil (Primary) ; Amlodipine
- Indications Diabetic nephropathies; Hypertension; Proteinuria
- Focus Therapeutic Use
- Acronyms OEDO-Study
- 16 Nov 2009 New trial record